-
05-08-2020, 09:14 AM
#561
Originally Posted by Not The Chosen One
Slowly but surely. Emphasis is on the word slowly, here
TruScreen strengthens its market presence in central and eastern Europe
As part of the rationalisation of its distributors network, Truscreen Limited
(NZX: TRU) ("the Company") is pleased to announce that it has appointed
prominent medical device distributor Aspironix, s.r.o (Aspironix) as its
exclusive distributor for Czech Republic, Slovakia, and Poland.
The territories of Czech Republic, Slovakia, and Poland, have a combined
cervical cancer addressable screening population of over 17.91 million women,
presenting a significant market opportunity for the Company.
Asprionix is a well-established specialised medical device distributor based
in Prague, with a rapidly growing turnover and increasing presence in central
and eastern Europe.
Together with Aspironix, the Company will develop a comprehensive market
access plan and have begun preliminary Key Opinion Leaders (KOL) engagement
for the region.
Truscreen CEO, Victoria Potarina, said "The distribution agreement with
Aspironix will enable us to significantly expand our distribution
capabilities in central and eastern Europe, bringing Truscreen's latest
real-time cervical cancer screening technology to the women of Czech
Republic, Slovakia and Poland.
The rationalisation of our distributor portfolio will see established and
committed medical device distributors, like Aspironix partnering with
Truscreen to bring our Truscreen cervical cancer screening technology to the
millions of women who are currently not covered by effective cervical cancer
screening."
All third world countries, ask yourself why is that ?
-
05-08-2020, 09:29 AM
#562
Member
Originally Posted by whatsup
All third world countries, ask yourself why is that ?
You do realise that they are targeting lower socioeconomic countries, right?
I know you're bitter about this company so kind of expected that response.
I see a lot of positives but it still may be a while before we see a success story (if at all) like PEB has recently
-
05-08-2020, 09:50 AM
#563
......and yet more good news. Steady progress being made here into a "significant market opportunity" (of 18million woman requiring screening) .
-
05-08-2020, 10:12 AM
#564
Junior Member
Great news. Good ethical investment option. Hopefully it makes a real difference for the women in those countries.
-
05-08-2020, 11:11 AM
#565
Member
As a big fan of the Czech Republic I'd say you might want to look at your definition of third world...
Originally Posted by whatsup
All third world countries, ask yourself why is that ?
-
05-08-2020, 12:21 PM
#566
Member
Originally Posted by MarineSalvage
As a big fan of the Czech Republic I'd say you might want to look at your definition of third world...
fair enough call.
The target market for TRU is Low and Middle Income Countries (LMIC's) with the lowest screening rates, highest
incidence and mortality rates.
The targeted countries have
- a lack of laboratory infrastructure
- no HPV vaccination programmes
- and have a shortage of diagnostic technicians
I believe their strategy is really solid, and they are making real progress in these very large markets. 58 hospitals already using Truscreen in China with another 30 planned in in the next few months looks really good!
-
05-08-2020, 02:03 PM
#567
Does it work though? Can it be independently verified as safe and effective? I worry that it might be a woo-woo device like that fake bomb detector in Iraq a few years back....
-
05-08-2020, 04:18 PM
#568
Member
Originally Posted by youngatheart
Does it work though? Can it be independently verified as safe and effective? I worry that it might be a woo-woo device like that fake bomb detector in Iraq a few years back....
From announcement 14/01/20
"The national All India Institute of Medical Sciences (AIIMS) conducted the trial involving 645 women at a tertiary referral centre in New Delhi and at a comprehensive rural health services centre at Ballabgarh, Haryana".
"All women in the trial underwent screening for CIN, using TruScreen’s opto-electrical device and a Pap test. The sensitivity of the TruScreen device to detect CIN was 81.82% compared to 72.73% by the Pap test. The specificity of the TruScreen device was 82.87% compared to 79.81% by the Pap test."
In 2019 the China study " exceeded expectations after Screening results from 2,065 women across 7 hospitals in Hunan, China."
"The Truscreen technology was acknowledged in the May 2019 Unitaid/WHO/Clinton Health Access Initiative (CHAI) report presented to the WHO Assembly in Geneva, Switzerland, as a suitable cervical cancer screening method for use in LMICs."
so yes, I believe this can be verified as safe and effective.
-
05-08-2020, 05:26 PM
#569
Member
-
05-08-2020, 07:08 PM
#570
Member
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks